Skip to content
Screener

Immunome IMNM Q1 2026 earnings

Reported May 12, 2026 · Before market open

Revenue-
EPS-$0.48Beat by $0.12
EPS estimate-$0.60

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$181.8K
EPS estimate-$0.64

Financials

Q1 2026

Income statement

See full
Revenue--100%
Operating income-$59.3M-32.9%
Net income-$53.8M-29.3%
EPS (diluted)-$0.48+7.7%

Balance sheet

See full
Cash & equivalents$582.7M+126%
Total debt$3.7M-22.6%
Total equity$588.7M+91.7%
Total assets$619.8M+80.9%

Cash flow

See full
Operating cash flow-$58.6M-10.5%
CapEx$3.0M-18.1%
Free cash flow-$61.6M-8.7%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$2.47B+323%
Enterprise value$1.9B+470%
P/S616.2×+563×

Profitability

See full
Operating margin-5,947.9%-12,002pp
Net margin-5,593.8%-11,284pp
FCF margin-5,118.9%-8,601pp

Returns & leverage

See full
Return on equity-50.1%-10.8pp
Debt / equity0×0.0×
Current ratio21.7×+11.2×

FAQ

When did Immunome report Q1 2026 earnings?
Immunome (IMNM) reported Q1 2026 earnings on May 12, 2026 before market open.
What were Immunome's Q1 2026 revenue and EPS?
Immunome reported revenue of - and eps of $-0.48 for Q1 2026.
Did Immunome beat estimates in Q1 2026?
EPS beat the consensus estimate of $-0.60 by $0.12.
How did Immunome's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 100.0% from $2.9M a year earlier and eps grew 7.7% from $-0.52.
Where can I find Immunome's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-219367) and the 10-Q periodic report (0001193125-26-219425) directly on SEC EDGAR. The filing index links above go to sec.gov.